Quotient Wealth Partners LLC Buys 374 Shares of Eli Lilly and Company $LLY

Key Points

• Quotient Wealth Partners LLC increased its stake in Eli Lilly and Company by 11.2%, owning a total of 3,726 shares worth approximately $2,905,000.
• A number of analysts have made adjustments to their price targets for Eli Lilly, with Deutsche Bank lowering their target from $1,010.00 to $900.00, while Goldman Sachs raised theirs slightly to $879.00.
• Insider trading activity included EVP Daniel Skovronsky purchasing 1,000 shares at an average cost of $634.40 per share, reflecting confidence in the company's future prospects.

Quotient Wealth Partners LLC increased its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 11.2% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 3,726 shares of the company's stock after buying an additional 374 shares during the period. Quotient Wealth Partners LLC's holdings in Eli Lilly and Company were worth $2,905,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also modified their holdings of the company. WestEnd Advisors LLC boosted its holdings in shares of Eli Lilly and Company by 210.0% during the 1st quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock worth $26,000 after buying an additional 21 shares during the period. Wealth Preservation Advisors LLC bought a new stake in shares of Eli Lilly and Company during the 1st quarter worth about $27,000. Citizens National Bank Trust Department boosted its holdings in shares of Eli Lilly and Company by 180.0% during the 1st quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock worth $35,000 after buying an additional 27 shares during the period. Financial Gravity Asset Management Inc. bought a new stake in shares of Eli Lilly and Company during the 1st quarter worth about $40,000. Finally, TD Capital Management LLC boosted its holdings in shares of Eli Lilly and Company by 129.2% during the 1st quarter. TD Capital Management LLC now owns 55 shares of the company's stock worth $46,000 after buying an additional 31 shares during the period. Institutional investors own 82.53% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the stock. Deutsche Bank Aktiengesellschaft cut their price objective on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a "buy" rating for the company in a report on Monday, August 11th. The Goldman Sachs Group boosted their price objective on shares of Eli Lilly and Company from $876.00 to $879.00 and gave the company a "buy" rating in a report on Friday, October 10th. Daiwa America downgraded shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a report on Sunday, August 17th. Morgan Stanley cut their price objective on shares of Eli Lilly and Company from $1,028.00 to $1,023.00 and set an "overweight" rating for the company in a report on Friday, October 3rd. Finally, UBS Group cut their price objective on shares of Eli Lilly and Company from $1,050.00 to $895.00 and set a "buy" rating for the company in a report on Friday, August 8th. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $939.12.

Insider Buying and Selling

In other news, EVP Daniel Skovronsky bought 1,000 shares of the company's stock in a transaction dated Tuesday, August 12th. The stock was bought at an average cost of $634.40 per share, for a total transaction of $634,400.00. Following the transaction, the executive vice president owned 137,660 shares of the company's stock, valued at $87,331,504. This represents a 0.73% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Jamere Jackson bought 200 shares of the company's stock in a transaction dated Friday, August 8th. The stock was purchased at an average price of $639.56 per share, with a total value of $127,912.00. Following the completion of the transaction, the director directly owned 9,402 shares in the company, valued at approximately $6,013,143.12. This represents a 2.17% increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders acquired 4,514 shares of company stock worth $2,894,841. 0.13% of the stock is owned by company insiders.

Eli Lilly and Company Price Performance

Shares of NYSE:LLY opened at $803.53 on Friday. The firm has a 50 day moving average of $753.09 and a 200-day moving average of $766.23. The stock has a market capitalization of $760.51 billion, a PE ratio of 52.52, a PEG ratio of 1.17 and a beta of 0.47. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $935.63.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, beating the consensus estimate of $5.59 by $0.72. The company had revenue of $15.56 billion during the quarter, compared to analysts' expectations of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business's revenue for the quarter was up 37.6% compared to the same quarter last year. During the same period in the previous year, the company earned $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, equities research analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.